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Background: The diagnosis of myalgic encephalomyelitis (ME/CFS) in research and
clinical practice has largely relied on clinical history, which can be subjective in nature.
Clinical signs are often subtle, overlap with other conditions, and are not formally included
as part of diagnostic workup. The characterization of clinical signs and biomarkers
is needed for better diagnosis and classification of patients and to monitor treatment
response. Hand grip strength (HGS) has been used as an objective measure of muscle
strength and fatigue, which is a primary symptom of ME/CFS. We assessed the potential
usefulness of HGS as a diagnostic marker in ME/CFS.
Methods: We compared HGS measurements from participants in the UK ME/CFS
Biobank, with groups consisting of people with ME/CFS of differing severity (n = 272),
healthy (n= 136), multiple sclerosis (n= 76) controls, and others with chronic fatigue not
meeting the diagnosis of ME/CFS (n = 37). We correlated the maximum and minimum
of, and differences between, 3 repeated HGS measurements with parameters of disease
severity, including fatigue and pain analog scales, and physical and mental component
summaries from the SF-36v2TM questionnaire across recruitment groups.
Results: HGS indicators were associated with having ME/CFS, with magnitudes of
association stronger in severely affected than in mild/moderately affected patients.
Compared with healthy controls, being severely affected was associated with a reduction
in minimum HGS of 15.3 kg (95%CI 19.3–11.3; p < 0.001), while being mild/moderately
affected was associated with a 10.5 kg (95%CI 13.2–7.8; p < 0.001) reduction. The
association persisted after adjusting for age, sex and body mass index. ME/CFS
cases also showed lower values of maximum HGS and significant drops in values
from the first to second and third trials, compared to other study groups. There were
significant correlations between HGS indicators and clinical parameters of disease
severity, including fatigue analog scale (Spearman’s Rho = −0.40, p < 0.001), pain
analog scale (Rho=−0.38, p< 0.001), and physical component summary (Rho= 0.42,
p < 0.001).
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Discussion: HGS is markedly reduced in ME/CFS, particularly in patients with more
severe disease, and may indicate muscle and fatigue related symptoms. HGS is a
potential diagnostic tool in ME/CFS, and could also be used to enhance patient
phenotyping and as an outcome measure following interventions
Keywords: ME/CFS, fatigue, biomarker, hand grip strength, severity, phenotyping
INTRODUCTION
Fatigue is common in the general population (1–3), and
often accompanies infections and chronic disorders of the
nervous, cardiovascular, respiratory, musculoskeletal, metabolic,
and endocrine systems as well as mood disorders, such as
depression and anxiety (4). It also commonly, and temporarily,
affects healthy individuals in certain circumstances, such as
following periods of excessive or prolonged physical or mental
effort, or reduced periods of rest or of good quality sleep.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
(ME/CFS) presents with disabling symptoms lasting for at least
6 months and resulting in a substantial reduction in activity
levels and quality of life (5–7). The etiology is unknown and
there are no diagnostic biomarkers for the disease. Prevalence
is difficult to determine, ranging from 0.1% to 0.7% (8). Among
other symptoms, including post-exertional malaise, unrefreshing
sleep, memory, and concentration problems, fatigue is the most
recognizable and is considered a central symptom of ME/CFS.
Nevertheless, fatigue may be difficult to characterize
and may be confounded by malaise, pain and other issues
such as somnolence, dyspnea (difficulty with breathing)
and muscle weakness. Patients may use several terms to
describe it, such as tiredness, lack of energy or “brain fog,”
to represent the difficulty or inability in initiating activity
(perception of generalized weakness) (9), reduced capacity
in maintaining activity (easy fatigability), and difficulty with
concentration, memory and emotional stability (mental
fatigue) (10).
The measurement of fatigue in research studies has been
subjective and has relied on questionnaires or scales. Symptoms
may be exaggerated or underestimated by the individual, and
they can vary according to cultural aspects and other factors,
such as the presence of other symptoms and mood changes. For
these reasons, objective measures of fatigue and disease status are
highly desirable, both for diagnostic and classification purposes
of people with ME/CFS.
Hand grip strength (HGS) is a reliable measurement of
localized muscle strength and reflects the force derived from
the combined contraction of extrinsic hand muscles. Originally
developed for hand surgery to determine capacity after trauma
or surgery, hand grip strength correlates well with other muscle
function tests such as knee extension strength (11). Moreover,
reduced HGS has been associated with morbidity and mortality,
with low values associated with falls, disability, impaired health-
related quality of life and prolonged length of stay in hospital
(11–13). It has also shown to be strongly correlated with post-
operative complications and has been reported as a predictor of
loss of functional status and short-term survival in hospitalized
patients (14, 15).
In this study, we assess the potential use of HGS parameters as
objective measures of disease status and severity in ME/CFS, and
correlate it with fatigue and pain severity and with physical and
mental functioning.
METHODS
Study Design and Population
This was an analytical cross-sectional study using baseline
data from participants in the UK ME/CFS Biobank (UKMEB).
Participants included people with amedically confirmedME/CFS
diagnosis from the UK National Health Service (NHS) and
assessed for compliance with study criteria, i.e., Centers for
Disease Control (CDC-94) (6) and/or Canadian Consensus
Criteria (CCC) (5); people with apparently normal function and
no symptoms of fatigue nor any severe disease (“healthy controls”
or “HC”); people with multiple sclerosis (MS) confirmed by an
NHS neurologist (“MS cases”); and people with chronic fatigue
not compliant with the study criteria (“CF/nonME”).
Procedures for recruitment, selection, and diagnosis have
been described previously (16). In summary, participants were
recruited through NHS general practices (GPs) and specialist
services. All potential UKMEB participants who were aged
18–60 years and gave informed consent were re-assessed by
the research team at the recruitment stage for eligibility into
the study, which included assessment for compliance with
ME/CFS diagnostic criteria for this cohort of participants. The
inclusion/exclusion criteria are summarized in Table 1. People
with ME/CFS (PWME) were then further stratified by disease
severity into two categories: mild/moderately affected (MEmm)
if they are ambulatory, and severely affected (MEsa) if they are
house- or bed-bound.
Ethical approval was granted by the London School of
Hygiene & Tropical Medicine (LSHTM) Ethics Committee
(ref. 6123), the National Research Ethics Committee (REC;
ref. 11/LO/1760, IRAS ID: 77765), and the NHS Research
Governance and Developments Offices (R&D), which oversee
the recruitment of research participants from government health
services.
Data Collection
Data collection ran from March 2012 to December 2015. The
study protocol was identical for all participants, regardless of
recruitment category.
HGS was quantified during the participant’s clinical
assessment and examination, by a team member (research
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TABLE 1 | UKMEB inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
ME/CFS cases: clinical diagnosis
according to CDC-1994 and/or Canadian
Consensus Criteria; diagnosis confirmed
by research nurse upon completing
baseline assessments
cases and controls:
- recent use (in preceding 3
months) of drugs known to
alter immune function, anti-viral
medications, and vaccinations
- history of acute and chronic
infections, such as hepatitis
B/C, tuberculosis, HIV, or other
severe illness or severe mood
disorders
- pregnant women and those
within 12 months post-partum
and/or currently lactating
CF/nonME: diagnosis of ME/CFS from
clinician but does not fulfill study criteria
upon completing baseline assessments
Healthy controls: no past or present
fatiguing and/or other major morbidity,
such as cancer or coronary heart disease
MS cases: confirmed diagnosis made
previously by NHS neurologist, in
compliance with the NICE guidelines
ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; CF/nonME, chronic
fatigue not meeting study criteria for ME/CFS; MS, multiple sclerosis; CDC, Centers for
Disease Control; NHS, National Health Services; NICE, National Institute for Health and
Care Excellence.
nurse or doctor), using a simple precision instrument that offers
a quantitative and objective measure of isometric muscular
strength of the hand and forearm. We followed standard
procedures using a Jamar Hydraulic Hand Dynamometer
(model #5030J1–JA Corp) for that aim (17). Participants were
seated with back, pelvis, and knees as close to 90 degrees as
possible. The shoulder was abducted and neutrally rotated with
the elbow flexed at 90 degrees, the forearm neutral, and the
wrist held between 0 and 15 degrees of ulnar deviation. The
dynamometer was presented vertically, in line with the forearm,
to the participant’s dominant hand. Grip size was adjusted for
comfort (9, 18). Participants were then instructed to squeeze
the hand grip as hard as they could, which took ∼ 3 s, in three
successive trials with 30 s in between each. The entire procedure
took∼ 3min to complete, including instructions.
The strength values were scored using force production in
kilograms (0–90). HGS has been shown to have excellent test-
retest reliability (intraclass correlations (ICC) 0.97–0.99) and
intra-rater reliability (ICC 0.96–0.98) in healthy adults (19) and
has been used in various diseases (20–22).
During the clinical assessment, alongside clinical parameters
that included height and weight, measures of fatigue and pain
intensity were recorded on fatigue (23) and pain (24) analog
scales, respectively. The fatigue and pain analog scales are
unidimensional measures of intensity and have been widely used
in diverse adult populations, e.g., in rheumatic diseases, chronic
hepatitis-C infection and systemic lupus (23–26). Each of them
can be described as a continuous scale comprised of a horizontal
line, 10 centimeters in length, and anchored by two vertical
descriptors, one for each symptom extreme (no fatigue/pain and
worst imaginable fatigue/pain). High scores, with a maximum of
10, indicate greater intensities of fatigue and pain. Fatigue and
pain analog scales have been shown to exhibit good test-retest
reliability (r = 0.94 for both) and to have high construct validity
with 5-point verbal descriptive scales (r = 71 and r = 0.78,
respectfully) (23, 24). Body mass index (BMI) in kg/m2 was
calculated using participants’ height and weight.
In addition, participants completed an extended
questionnaire, which includes the SF-36V2TM questionnaire (27),
the Fatigue Severity Scale (FSS) (28), and socio-demographic
data, such as age and sex, among other variables. The SF-36v2TM
comprises of 36 questions providing information on functional
status and well-being (29). The answers form eight distinct
domains considering physical and mental functions, were
summarized into physical (PCS) and mental (MCS) component
summary scores. Low scores indicate reduced functional status
and reduced mental vitality, respectively. The SF-36v2TM is
recognized as a reliable tool that has been used and validated
across different populations, and has been used extensively in
ME/CFS [L. a. (7, 30, 31)]. A full report of the development
of this instrument has been published elsewhere (29). The FSS
contains 9 items that relate to statements of fatigue, which are
scored between 1 (strongly disagree) and 7 (strongly agree) by
the participant. The total score is calculated by adding those
attributed to each question, and varies from 9 to 63. Due to the
strong correlation between FSS and the fatigue analog scales (r =
0.8, p < 0.001 in our sample), we opted to use the latter only in
our analysis.
Statistical Analysis
Answers to the SF-36v2TM questions were scored in health
domains using the SF Health OutcomesTM Scoring Software
4.5 (QualityMetric Inc., RI, United States) and are presented
as “normalized” physical and mental summary scores.” Data
were analyzed using STATATM version 15.0 (StataCorp, TX,
United States). The maximum and minimum (of three
measurements) of HGS were obtained for each participating
individual.
Descriptive characteristics were obtained for the whole study
population, separated by category of recruitment. Histograms
of HGS were visually inspected for shape of distributions.
For categorical variables, total numbers and percentages were
obtained. For continuous variables, means and standard
deviations were provided for normally distributed variables
and medians and inter-quartile ranges otherwise. Mean scores
(and standard deviations) were calculated for the hand grip
strength values. Chi-squared tests and ANOVA F-statistics were
used in simple univariate analyses to compare categorical and
continuous variables between recruitment categories (32).
To investigate whether HGS was associated with being
a ME/CFS case, we plotted minimum and maximum HGS
(HGSmin and HGSmax, respectively) against recruitment
categories. Bivariate linear regression was used to further explore
the associations with indicators of HGS entered into the model
as a continuous score and healthy controls (HC) as the baseline
comparator. We then adjusted for potential confounding by age,
gender, and BMI in multivariate regression analyses.
To examine the change in HGSmin and HGSmax over the
three successive measurements, we plotted their means at each
time point within each recruitment category. Differences between
HGS indicators (HGSmax and HGSmin) means at each time point
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were compared in the following way: time point 1–time point 2,
time point 1–time point 3, and time point 2–time point 3.
As the difference between mean HGS at the second and third
time points was not statistically different (p= 0.21) in the overall
study population or in any of the study groups, the average of
these two measurements was used for calculating the difference
between the first and a subsequent measurement. Therefore, the
difference between the first and the average of 2nd and 3rd values
represented the overall drop or increase in HGS over subsequent
trials, referred to as the HGS-difference (HGSdiff). Positive values
represent a drop in values from the first to subsequent trials.
Paired t-tests were used to determine whether the means were
significantly different within recruitment categories.
To examine whether HGS was correlated with parameters
of disease severity, Spearman’s rank-order correlations were
computed. A correlation matrix was obtained, and graphs
produced. To further explore the association of disease severity
parameters with indicators of HGS, multivariate regression
analyses were performed adjusting for recruitment category, age,
sex, and BMI.
RESULTS
The distributions of participant characteristics by recruitment
category are shown in Table 2. Females were over-represented
(72%) in the study. Mean age varied across study groups;
HC (45.4 years; 95% Confidence Interval (CI) 43.4, 47.4) and
CF/nonME (45.4 years; 95%CI 43.4, 47.4) were slightly younger
and cases of MS were slightly older (52.5 years; 95%CI 50.6, 54.4).
Mean BMI ranged from 24.3 (95%CI 23.0, 25.7) in MEsa to 26.4
(95% ci 25.3, 27.4) in MEmm.
The mean values for the fatigue analog scales were 7.4 (95%CI
7.0, 7.7) for MEsa and 6.7 (95%CI 6.4, 7.0) for MEmm. These
values were significantly (p < 0.0001) higher than for HC
(1.5; 95%CI 1.2, 1.8), CF/nonME (4.5; 95%CI 3.4, 5.5) and MS
cases (5.4; 95%CI 4.7, 5.9). The pain analog scales were also
significantly higher in ME/CFS cases (P < 0.0001); the mean
values were: 5.3 (95%CI 4.6, 6.0) for Mesa, 4.9 (95%CI 4.6, 5.3)
forMEmm, and 1.0 (95%CI 0.7, 1.2) for HC, with values for other
groups in between these. The Physical Component Summary
(PCS) in particular, and also Mental Component Summary
(MCS) scores were much lower (p < 0.001) in MEsa, (19.0 PCS;
95%CI 17.7, 20.4 and 44.2 MCS; 95%CI 41.4, 46.9) and MEmm
(31.0 PCS; 95%CI 30.0, 32.2 and 39.2 MCS; 95%CI 37.8, 40.6)
compared with HC (57.0 PCS; 95%CI 56.2, 57.9 and 52.1 MCS;
95%CI 50.7, 53.5), CF/nonME (45.7 PCS; 95%CI 42.9, 48.6 and
43.7 MCS; 95%CI 40.6, 46.8) and MS cases (38.4 PCS; 95%CI
35.6, 41.2 and 46.1 MCS; 95%CI 43.6, 48.5), indicating reduced
functional status and mental vitality among people with ME/CFS
(Table 2).
When mean values of HGS were observed over time (i.e.,
over successive trials), no trend was seen within HC, MS cases,
and CF/nonME (Figure 1). Among these recruitment categories,
there was a slight (non-significant) drop in values between the
first and second trials, which was typically followed by a slight
increase in values from the second to the third trials. A similar
trend was found for MEmm, except that the drop in values
between the 1st and 2nd trials was more marked (p < 0.01).
However, amongMEsa, the mean HGS decreased markedly from
first, to second (P = 0.03), and then again to the third time point
(P = 0.13), whereas HGS for MEmm increased from second to
third trial (P = 0.19).














Sex N(%) Females 84 (62.8) 59 (77.6) 24 (64.9) 166 (76.9) 43 (76.8) 0.02
Age mean(SD) 45.4 (12.0) 52.5 (8.4) 45.4 (10.3) 47.1 (11.0) 45.9
(11.5)
0.0001
BMI mean(SD) 24.9 (4.3) 26.3 (6.1) 24.7 (5.2) 26.4 (6.0) 24.3 (5.0) 0.04
hand grip1 mean(SD) 34.4 (13.9) 23.1 (11.8) 32.2 (15.5) 25.2 (11.9) 21.2 (9.7) <0.0001
hand grip2 mean(SD) 33.9 (14.0) 22.5 (12.9) 31.4 (17.2) 23.5 (12.6) 19.2 (9.2) <0.0001
hand grip3 mean(SD) 34.1 (14.2) 22.6 (12.7) 31.4 (18.1) 23.9 (12.4) 18.5 (9.2) <0.0001
min hand grip mean(SD) 32.0 (13.8) 20.3 (12.0) 29.0 (16.8) 21.6 (11.9) 16.7 (9.2) <0.0001
max hand
grip
mean(SD) 36.2 (14.1) 25.1 (12.4) 34.2 (16.8) 27.1 (12.2) 22.9 (9.2) <0.0001
Fatigue
Analog Scale
mean(SD) 1.5 (1.5) 5.3 (2.5) 4.5 (2.2) 6.7 (1.6) 7.4 (1.4) <0.0001
Pain Analog
Scale
mean(SD) 1.0 (1.5) 3.4 (2.7) 2.2 (2.0) 4.9 (2.5) 5.3 (2.7) <0.0001
PCS mean(SD) 57.0 (4.9) 38.4 (12.2) 45.7 (8.4) 31.0 (8.6) 19.0 (4.7) <0.0001
MCS mean(SD) 52.1 (8.1) 46.1 (10.8) 43.7 (9.0) 39.2 (9.9) 44.2 (9.9) <0.0001
*χ2 for categorical variables; F-statistic for continuous variables. HC, healthy controls; MS, multiple sclerosis; CF/nonME, chronic fatigue not meeting study criteria for ME/CFS; MEmm,
ME/CFS mild/moderately affected; MEsa, ME/CFS severely affected; BMI, body mass index; PCS, physical component summary; MCS, mental component summary; SD, standard
deviation.
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FIGURE 1 | Mean hand grip strength at each time point within each
recruitment category. HC, healthy controls; MS, multiple sclerosis; CF/nonME,
chronic fatigue not meeting study criteria for ME/CFS; MEmm, ME/CFS
mild/moderately affected; MEsa, ME/CFS severely affected.
Associations of Hand Grip Strength
Parameters With Being a ME/CFS Case
(HGSmax, HGSmin, and HGSdiff)
The mean of the HGSmax measurements was highest among HC
(36.2 kg; 95%CI 33.8, 38.6) and lowest among MEsa (22.9 kg;
95%CI 20.4, 25.4) (p< 0.0001). The same was true for the average
HGSmin measurements, with HC producing a mean of 32.0 kg
(95%CI 30.7, 33.4) and MEsa,16.7 kg (95%CI 14.2, 19.2). Among
HC, MS and CF/nonME cases, both the HGSmax and HGSmin
values were similar (Figure 2).
Table 3 shows the difference between HGS parameters of
various study groups and HCs, with negative values indicating
values below that of HCs. Compared with HCs, the values
of HGmin were on average 15.3 kg lower in MEsa (−15.3 Kg;
95%CI −19.3, −11.3), 11.8 kg lower in MS cases (−11.8 kg;
95%CI −15.3, −8.2), and 10.5 kg lower in MEmm cases
(−10.5 kg; −13.2, −7.8). These differences were all statistically
significant at P < 0.001. CF/nonME values were similar to that
of HCs (−3.0; 95%CI −7.6, 1.5; P = 0.19). The same trend was
found for HGSmax but was less pronounced. After adjusting for
age, sex, and BMI, changes in mean HGS compared with HC
were attenuated for all but CF/nonME. MEsa still showed the
lowest HGSmin value (−10.2 kg; 95%CI −13.3, −7.1) compared
with HC, however MS cases (−5.9 kg; 95%CI −8.8, −2.9) now
showed similar values to CF/nonME cases (−5.5; 95%CI −10.0,
−1.0).
The results for the HGSdiff are shown in Table 4. Overall, for
all recruitment categories, there was a slight decrease in mean
HGSdiff (1.07 kg; 95%CI 0.68, 1.47; p < 0.001). For HC (0.39 kg;
95%CI−0.20, 0.99 p= 0.19), MS cases (0.64; 95%CI−0.32, 1.60;
p = 0.19), and CF/nonME (0.79; 95%CI −0.74, 2.32; p = 0.30),
none of these differences were significant. However, for ME/CFS
cases (both MEmm and MEsa), the HGSdiff were higher and
statically significant (P < 0.01).
Correlations of Hand Grip Strength With
Parameters of Disease Severity
Overall, HGSmax and HGSmin were low to moderately correlated
with clinical parameters of disease severity, including fatigue and
pain analog scales and PCS, but weakly correlated with MCS
(Supplementary Table 1).
Results from bivariate and multivariate regression analyses
for the association of HGS indicators and parameters of disease
severity are presented in Table 5. For every one unit increase in
kilograms of HGSmin, fatigue severity and pain severity analog
scales decreased by 0.23 (95%CI −0.29, −0.17) and 1.47 (95%CI
−1.86, −1.08), respectively. Alternatively, PCS increased by
0.33 kg (95%CI 0.26, 0.41) and MCS increased by 0.21 kg (95%CI
0.10, 0.32) for each unit increase in kilograms of HGSmin. The
same can be seen for HGSmax, but less markedly. Adjustment for
the variables age, sex, and BMI resulted in slightly weaker, but still
significant, associations in all cases.
DISCUSSION
Concepts of Fatigue, Strength, Physical
Functioning, and Their Measurement
The concept of fatigue ismultidimensional and lacks a universally
accepted definition. It may be central or peripheral in origin.
Central fatigue refers to a state of less-than-optimal outputs
from the brain, in particular, from cortical motor area to
motor units where nervous fibers stimulate muscle fibers to
produce contraction. In contrast, peripheral fatigue represents an
impairment of the contractile function of skeletal muscle fibers
and the inability of the muscle to produce force (33, 34).
In ME/CFS, fatigue is a key symptom, used for the diagnosis
and the assessment of disease severity. However, there is no
single descriptor that accurately defines it. It is usually assessed
by direct questioning and reported presence of the symptom
during diagnosis workup; symptom classifiers may include
duration, frequency, persistence or recurrence, and intensity.
When establishing compliance with diagnostic criteria, people
may be asked, for example, how long they have experienced
fatigue, and whether it is present for more than 50% of the time.
Questionnaires, such as the UKMEB symptoms assessment
or clinical phenotyping questionnaires (16), or the DePaul
Symptoms Questionnaire (35) have been used to establish the
presence and severity of fatigue and other symptoms. The fatigue
(23) and pain analog scales (24), which are used in this study,
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FIGURE 2 | Means of maximum and minimum hand grip strengths within recruitment categories, with 95% confidence intervals. HC, healthy controls; MS, multiple
sclerosis; CF/nonME, chronic fatigue not meeting study criteria for ME/CFS; MEmm, ME/CFS mild/moderately affected; MEsa, ME/CFS severely affected.
TABLE 3 | Crude and adjusted associations of minimum and maximum hand grip
strengths with recruitment categories, compared with healthy controls using
ANOVA.
Crude Adjusted*
Factors Change in mean
HGS kg (95%CI)





MS controls −11.8 (−15.3, −8.2) <0.001 −5.9 (−8.8, −2.9) <0.001
CF/nonME −3.0 (−7.6, 1.5) 0.19 −5.5 (−10.0, −1.0) 0.02
MEmm −10.5 (−13.2, −7.8) <0.001 −7.6 (−10.1, −5.1) <0.001
MEsa −15.3 (−19.3, −11.3) <0.001 −10.2 (−13.3, −7.1) <0.001
HGSmax
HC 0.0 0.0
MS controls −11.0 (−14.7, −7.4) <0.001 −5.3 (−8.2, −2.4) <0.001
CF/nonME −2.0 (−6.6, 2.7) 0.41 −4.3 (−8.8, 0.24) 0.06
MEmm −9.1 (−11.8, −6.3) <0.001 −6.1 (−8.6, −3.5) <0.001
MEsa −13.3 (−17.3, −9.2) <0.001 −7.9 (−11.1, −4.8) <0.001
*adjusted for sex, age, and BMI **t-statistic. HC, healthy controls; MS, multiple sclerosis;
CF/nonME, chronic fatigue not meeting study criteria for ME/CFS; MEmm, ME/CFS
mild/moderately affected; MEsa, ME/CFS severely affected; BMI, body mass index.
are simple and widely used instruments to ascertain fatigue
and pain severity; they do, however, rely on self-reporting.
This undoubtedly carries some subjectivity and, although both
internal validity and test-retest reliability have been shown to
be high (24), it is more difficult to establish comparability in
the way different individuals interpret and report on fatigue and
its severity. This may be particularly problematic in the case of
TABLE 4 | Comparison of difference between hand grip strength at time point 1
and the average of hand grip strength at time points 2 and 3 within each
recruitment category, using paired t-test.
Paired Differences (hand grip 1–avg hand
grip 2 and 3)
95% CI
Pairs Mean Lower Upper p-value
Overall 1.07 0.68 1.47 <0.001
HC 0.39 −0.20 0.99 0.19
MS cases 0.64 −0.32 1.60 0.19
CF/nonME 0.79 −0.74 2.32 0.30
MEmm 1.38 0.75 2.01 <0.0001
MEsa 2.38 0.54 4.22 0.01
HC, healthy controls; MS, multiple sclerosis; CF/nonME, chronic fatigue not meeting study
criteria for ME/CFS; MEmm, ME/CFS mild/moderately affected; MEsa, ME/CFS severely
affected.
ME/CFS, where the experience of fatigue is usually both physical
andmental–described as “lack of stamina or physical energy” and
“brain fog and cognitive problems,” respectively—and is closely
associated with a range of other symptoms. Such symptoms
may or may not be interpreted as part of the same symptom
complex, which may include post-exertional malaise, pain, flu-
like symptoms and unrefreshing sleep, to name a few associated
symptoms. The pathological fatigue experienced by people with
ME/CFS, which some refer to as “ME fatigue”, to distinguish from
fatigue or tiredness that represent everyday experience, may be
very hard to express and quantify in objective terms.
Frontiers in Neurology | www.frontiersin.org 6 November 2018 | Volume 9 | Article 992
Nacul et al. Hand Grip in ME/CFS
















−0.23 (−0.29, −0.17) <0.001 −0.14 (−0.20, −0.08) <0.001
Pain analog
scale
−1.47 (−1.86, −1.08) <0.001 −0.93 (−0.17, −0.69) <0.001
PCS 0.33 (0.26, 0.41) <0.001 0.24 (0.17, 0.31) <0.001




−0.20 (−0.26, −0.13) <0.001 −0.13 (−0.19, −0.07) <0.001
Pain analog
scale
−1.29 (−1.68, −0.89) <0.001 −0.84 (−1.07, −0.60) <0.001
PCS 0.30 (0.22, 0.37) <0.001 0.24 (0.18, 0.31) <0.001
MCS 0.17 (0.06, 0.28) <0.001 0.07 (0.01, 0.13) 0.03
*adjusted for recruitment category, age, sex, and BMI; **t-statistic. PCS, physical
component summary; MCS, mental component summary; BMI, body mass index.
The experience of fatigue or of feeling ill (with ME/CFS)
may also be measured indirectly through the impact on people’s
lives, such as on the ability of individuals to perform physical
or mental tasks, including self-care or engaging in work, study
and social activities. Some fatigue scales incorporate the impact of
fatigue on functioning (28), but more generally, instruments that
measure functionality or quality of life have been used to indicate
the impact of the health status on individuals affected. The SF-
36v2TM is one such well-validated and widely used instrument,
and we used in our analyses the Physical and Mental Component
Summaries derived from answers given by participants, as proxy
measures for the impact of fatigue and disease on the life of
individuals studied.
With the challenges involved in measuring fatigue, and more
broadly disease severity in ME/CFS, the importance of an
objective measurement cannot be overestimated, particularly one
which could be used in research studies to aid diagnosis and
clinical phenotyping. Assessments indicating levels of severity
and impact could be used on a longitudinal basis to inform
disease progress and, potentially, disease prognosis.
Hand Grip Strength as a Tool for Measuring
Disease Status
Although the testing of HGS was originally created to evaluate
patients undergoing hand surgery, this measurement has been
shown to be associated with reduced muscle strength and
decreased physical fitness more broadly (36). The latter is one
of the strongest predictors of individual future health status,
characterized by the ability to perform daily activities with vigor
and without overdue fatigue. Physical fitness is an important
predictor ofmortality andmorbidity for older and younger adults
and teenagers, which can be applied in socially, economically and
culturally diverse populations (36–39).
Reduced muscle strength and decreased hand grip have been
associated with a few specific situations, such as muscle or nerve
injury and malnutrition. More broadly, though, grip strength has
been shown to be a simple, yet powerful indicator of overall
physical health status and as a predictor of future disability,
morbidity, health deterioration (40) and mortality (15), and to
assess treatment in various diseases, such as chronic obstructive
pulmonary disease (41) and rheumatoid arthritis (20, 42). HGS
has also been used to predict cardiovascular risk in pre-diabetic
and diabetic patients (38). Associations of poor HGS and future
disability and mortality have been observed even among healthy
subjects (43), suggesting it could perhaps be used as an early,
though nonspecific, indicator of risk for health deterioration.
The underlying mechanisms explaining the association
between grip strength and health status are poorly understood,
except in cases where local factors such as upper limb muscle
damage are in place. Nevertheless, there is sufficient evidence
that HGS is a measurement of not only muscle strength, but
also of overall physical health.However, unlike cardiorespiratory
fitness testing, which demands special location and equipment,
measurement of HGS is a simple and mobile tool; making them
particularly useful for community-based health evaluations,
especially for severe cases of ME/CFS, who normally are house-
bound.
Summary of Results and Interpretation
Overall, patients with ME/CFS and MS had significant lower
HGS values thanHC.MS is themost common immune-mediated
inflammatory demyelinating disease of the central nervous
system. One of the most prominent features of MS is motor
weakness. Therefore, it is expected people with MS to display
lower HGS (44, 45). However, it is interesting that ME/CFS
patients also had significantly lower HGS values compared toHC,
even after controlling for age, sex, and BMI, with even mild cases
showing lower HGS. People with ME/CFS are not malnourished
and have preservedmuscle tonus, suggesting that other than local
factors related to the integrity of upper limbmust be involved.We
suggest these might relate to ongoing inflammation or disruption
of signaling mechanisms between central nervous system and
periphery, and it may also represent an overall measurement of
“physical health and functioning.”
Furthermore, HGS among people with ME/CFS significantly
dropped in measured strength between the first and subsequent
trials, when compared with HC. This effect was not observed
in cases of MS nor in those with chronic fatigue which did
not meet the criteria for ME/CFS. This finding may relate to
early fatigability, where an already reduced ability to produce
substantive muscle power in the first trial is further compromised
in subsequent attempts. The understanding of the mechanisms
behind the lack of rapid recovery in demonstrable muscle force
produced between subsequent (hand grip) trials, may be the key
to explaining the pathological nature of fatigability and post-
exertional symptoms in people with ME/CFS. It is possible that
disruptions in muscle energy metabolism or in the continuous
production and release of energy by muscle cells, or in nervous
system signaling could be involved, however, further experiments
would be required for any conclusions to be made.
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We have also shown that higher HGS was associated with
lower fatigue and pain intensities and with higher functional
status and mental vitality. The correlations were stronger for
physical than mental component summaries of the SF-36v2TM,
suggesting a lesser role for lack of motivation as a single factor
explaining poorer results in those with ME/CFS. Such significant
correlations of HGS values and indicators of symptom severity
and disease status provide further indications for the value
of including of HGS as an objective test to enhance patient
phenotyping in ME/CFS as part of clinical practice and in
research.
Our results are in line with previous small studies, and
reinforce the importance of HGS as part of the clinical assessment
of people with ME/CFS (46). Patients meeting the CDC-94
criteria for ME/CFS (6) had previously shown significantly
reduced HGSmax compared to non-fatigued individuals, with
example values for right hand force of 31Kg inME/CFS vs. 42Kg
in healthy sedentary controls (n = 8 in each group) (47) and
24.3 Kg in ME/CFS vs. 35.8 Kg in healthy controls (n= 30 and 15
in CFS and controls, respectively) (48). However, no difference
in values was found comparing PWME to those with major
depression (48). HGS was also used to assess the effects of an
exercise intervention among 11 women with ME/CFS meeting
either CDC-1994 (6) or International Consensus Criteria [B.
M. (49)], who showed a significant improvement in left hand
HGS (from 20 to 26Kg), but not in right hand HGS following
the intervention (50), suggesting a role for HGS as an outcome
measure in the evaluation of interventions. People with ME/CFS
were also previously shown to have slower and incomplete
recovery of HGS values following effort challenge, compared with
non-fatigued (51, 52) and controls with MS (51). These studies
included 48 and 10 ME/CFS cases, respectively.
Study Strengths and Limitations
The study included a relatively large number of participants
with ME/CFS (N = 272), including different levels of
severity, and used both healthy and diseased individuals for
comparison groups.We used standardizedmethods for diagnosis
and characterization of participants, which included rigorous
procedures for selection, clinical assessment and phenotyping,
according to the UK ME/CFS Biobank protocol (16). This
was, however, an observational cross-sectional study, and the
use of HGS as a diagnostic tool and the mechanisms by
which variation in values reflect pathophysiology will require
further studies. Similarly, validation of the study in individuals
with a range of disease durations, including those with more
recent disease as well as in different geographical locations and
ethnicities, will be needed to widen the representativeness of the
study to other populations and in patients at various disease
stages. Furthermore, there are multiple types of MS, and by
combining cases of MS all into one category, the results may
have been diluted. However, this is not likely to have made a
significant difference as differences in dynamic fatigability have
been found when comparing MS and healthy controls but not
when comparing types of MS (45).
CONCLUSIONS AND IMPLICATIONS
In this study, we investigated the potential use of HGS as
an objective measure of disease status and severity in people
with ME/CFS and assessed the correlation of HGS with
fatigue/pain severity and physical/mental functioning. HGS
was markedly reduced in people with ME/CFS, particularly
in those who were severely affected. Furthermore, strength
decreased with each successive measurement among people with
ME/CFS, which suggests early fatigability, or that they tire
more easily than healthy or diseased controls. The abnormal
pattern of handgrip strength shown in ME/CFS cases give
further indications of the distinct nature of ME/CFS and
shed more light into the pathological nature of the fatigue
symptom complex experienced by those with the disease. The
exact mechanisms involved in reduced power and fatigability
require further exploration. Nevertheless, the results shown
here have practical implications in better defining a fatigue
phenotype that help identify cases of ME/CFS and that can be
used as an objective tool for diagnosis and measuring disease
severity.
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